Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) saw an uptick in trading volume on Wednesday after Needham & Company LLC raised their price target on the stock from $30.00 to $33.00. Needham & Company LLC currently has a buy rating on the stock. 1,343,090 shares traded hands during mid-day trading, an increase of […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $16.02, for a total value of $160,200.00. Following the completion of the sale, the insider now owns 1,174,662 […]
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most.
Piper Sandler reiterated their overweight rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) in a research note released on Tuesday, Benzinga reports. Piper Sandler currently has a $40.00 price target on the stock. Several other research analysts have also recently issued reports on DAWN. Oppenheimer reaffirmed a market perform rating on shares […]
Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have received an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating […]